Securian Asset Management Inc. lowered its stake in shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,261 shares of the medical research company’s stock after selling 328 shares during the quarter. Securian Asset Management Inc.’s holdings in PerkinElmer were worth $1,439,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Accurate Wealth Management LLC acquired a new stake in shares of PerkinElmer in the 4th quarter worth $27,000. FourThought Financial LLC purchased a new position in shares of PerkinElmer in the 3rd quarter valued at about $42,000. Alta Advisers Ltd purchased a new position in shares of PerkinElmer in the 3rd quarter valued at about $60,000. Dupont Capital Management Corp purchased a new position in shares of PerkinElmer in the 4th quarter valued at about $61,000. Finally, Covestor Ltd raised its position in shares of PerkinElmer by 25.1% during the 1st quarter. Covestor Ltd now owns 359 shares of the medical research company’s stock worth $63,000 after acquiring an additional 72 shares in the last quarter. Institutional investors and hedge funds own 85.22% of the company’s stock.
Insiders Place Their Bets
In other PerkinElmer news, insider Andrew Okun sold 1,851 shares of the company’s stock in a transaction dated Tuesday, April 11th. The stock was sold at an average price of $135.01, for a total transaction of $249,903.51. Following the completion of the sale, the insider now directly owns 8,580 shares in the company, valued at $1,158,385.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other PerkinElmer news, insider Daniel R. Tereau sold 10,741 shares of the company’s stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $123.72, for a total transaction of $1,328,876.52. Following the completion of the sale, the insider now directly owns 11,611 shares in the company, valued at $1,436,512.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Okun sold 1,851 shares of the company’s stock in a transaction dated Tuesday, April 11th. The stock was sold at an average price of $135.01, for a total value of $249,903.51. Following the sale, the insider now owns 8,580 shares of the company’s stock, valued at $1,158,385.80. The disclosure for this sale can be found here. Insiders sold 15,349 shares of company stock worth $1,953,042 over the last three months. 0.52% of the stock is owned by insiders.
PerkinElmer Stock Performance
PerkinElmer (NYSE:PKI – Get Rating) last released its earnings results on Tuesday, February 14th. The medical research company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.66 by $0.04. The firm had revenue of $741.20 million during the quarter, compared to analyst estimates of $1.07 billion. PerkinElmer had a return on equity of 13.94% and a net margin of 14.69%. The business’s quarterly revenue was down 27.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.56 earnings per share. Equities research analysts anticipate that PerkinElmer, Inc. will post 5.07 earnings per share for the current year.
PerkinElmer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, May 12th. Shareholders of record on Friday, April 21st will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, April 20th. This represents a $0.28 annualized dividend and a yield of 0.21%. PerkinElmer’s dividend payout ratio is presently 6.11%.
Analyst Ratings Changes
Several brokerages have recently weighed in on PKI. Robert W. Baird cut their target price on PerkinElmer from $185.00 to $182.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 15th. TheStreet raised PerkinElmer from a “c+” rating to a “b” rating in a report on Tuesday, February 14th. Credit Suisse Group reissued a “neutral” rating and issued a $160.00 target price on shares of PerkinElmer in a report on Wednesday, February 15th. StockNews.com began coverage on PerkinElmer in a research note on Thursday, March 16th. They issued a “hold” rating on the stock. Finally, Barclays decreased their target price on PerkinElmer from $145.00 to $140.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 24th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $166.30.
About PerkinElmer
PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments.
Featured Articles
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- Medtronic: Reversal In-Play For This High-Yield Stock
- Is it ‘Game Over’ for Roblox After Reporting March Metrics Miss?
- Is it Time to Take Profits in Chip Stocks?
- Will Stratasys Continue to be a Runaway Bride?
- Garrett Motion Inc. Skids on Results: Is it Time to Buy the Dip?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
